News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,542 Results
Type
Article (578)
Company Profile (1)
Press Release (2963)
Section
Business (997)
Career Advice (2)
Deals (151)
Drug Delivery (1)
Drug Development (907)
FDA (175)
Job Trends (131)
News (2114)
Policy (325)
Tag
Academia (20)
Accelerated approval (1)
Adcomms (3)
Alliances (329)
ALS (1)
Alzheimer's disease (310)
Antibody-drug conjugate (ADC) (4)
Approvals (174)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (93)
Biosimilars (1)
Brain cancer (1)
Breast cancer (3)
Cancer (47)
Cardiovascular disease (4)
Career advice (2)
Cell therapy (2)
Clinical research (622)
Collaboration (12)
Compensation (1)
COVID-19 (10)
C-suite (8)
Data (39)
Depression (1)
Diagnostics (31)
Digital health (1)
Drug discovery (4)
Drug pricing (2)
Duchenne muscular dystrophy (4)
Earnings (269)
Editorial (3)
Events (502)
Executive appointments (7)
FDA (202)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (4)
Gene therapy (2)
GLP-1 (24)
Government (36)
Guidances (1)
Healthcare (37)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (4)
Immuno-oncology (1)
Infectious disease (10)
Inflammatory bowel disease (3)
Intellectual property (1)
IPO (75)
Job creations (37)
Job search strategy (1)
JPM (3)
Layoffs (13)
Leadership (1)
Legal (43)
Liver cancer (4)
Lung cancer (8)
Lymphoma (6)
Manufacturing (4)
Medical device (10)
Medtech (10)
Mergers & acquisitions (82)
Metabolic disorders (7)
Multiple sclerosis (3)
Neurodegenerative disease (47)
Neuropsychiatric disorders (1)
Neuroscience (328)
NextGen: Class of 2026 (20)
Non-profit (12)
Now hiring (1)
Obesity (7)
Opinion (5)
Ovarian cancer (7)
Pain (2)
Parkinson's disease (1)
Patents (1)
Patient recruitment (5)
People (348)
Pharmaceutical (1)
Phase 1 (130)
Phase 2 (232)
Phase 3 (328)
Pipeline (35)
Policy (6)
Postmarket research (30)
Preclinical (41)
Psychedelics (1)
Rare diseases (10)
Real estate (38)
Regulatory (301)
Reports (1)
Research institute (11)
Schizophrenia (13)
Series A (2)
Series B (1)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (1)
Startups (17)
Stomach cancer (1)
Tariffs (1)
The Weekly (10)
Vaccines (7)
Weight loss (3)
Date
Last 7 days (3)
Last 30 days (12)
Last 365 days (178)
2026 (17)
2025 (190)
2024 (175)
2023 (211)
2022 (268)
2021 (254)
2020 (217)
2019 (311)
2018 (216)
2017 (179)
2016 (168)
2015 (158)
2014 (131)
2013 (170)
2012 (201)
2011 (190)
2010 (138)
Location
Africa (4)
Asia (533)
Australia (8)
California (14)
Canada (5)
China (9)
Colorado (2)
Europe (459)
Florida (16)
Japan (36)
Maryland (1)
Massachusetts (57)
New Jersey (40)
New York (10)
North Carolina (1)
Northern California (7)
Pennsylvania (12)
South America (6)
Southern California (6)
Texas (7)
United States (160)
Washington D.C. (1)
Washington State (2)
Wisconsin (2)
3,542 Results for "eisai inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space
Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his company’s own anti-tau asset, while others suggest the Alzheimer’s field is heading in a completely different direction.
December 5, 2025
·
4 min read
·
Heather McKenzie
FDA
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More
Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s Alzheimer’s drug Leqembi, which, according to Eisai, could “help reduce the burden on healthcare professionals and patients.”
August 11, 2025
·
5 min read
·
Tristan Manalac
Approvals
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.
September 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
January 12, 2026
·
13 min read
Alzheimer’s disease
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
March 26, 2025
·
2 min read
·
Tristan Manalac
Press Releases
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
January 7, 2026
·
9 min read
Press Releases
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 2, 2025
·
4 min read
Press Releases
Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
November 4, 2025
·
25 min read
Press Releases
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
November 28, 2025
·
12 min read
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American headquarters in Nutley, New Jersey. A company spokesperson said the pharma remains fully committed to the U.S. market.
February 28, 2025
·
1 min read
·
Angela Gabriel
1 of 355
Next
